Trial Profile
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Zydus Discovery DMCC
- 03 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 03 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 08 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.